Loading...
Recent understanding of the structure and function of the androgen receptor and insights into the phenomenon of resistance to testosterone suppression in patients with metastatic prostate cancer managed with androgen deprivation therapy (ADT) have been accompanied by therapeutic developments such as the androgen biosynthesis inhibitor abiraterone acetate (JW Oncol Hematol May 25 2011). In addition, a second-generation antiandrogen agent, enzalutamide (MDV3100), was developed to have activity against prostate cancer cell lines resistant to the first-generation antiandrogen bicalutamide (Science 2009; 324:787). Prior phase I and II data demonstrated the efficacy and safety of this agent in patients with advanced prostate cancer (Lancet 2010; …